Автор статьи:  Мусагалиева А.Т.

Соавторы:  Имантаева Г.М., Тохтасунова С.В., Наринбаев А.С., Маханов Д.И., Колесников А.Е., Садвакасова Г.А., Оспанова Ф.С.

Место работы автора:  Научно-исследовательский институт кардиологии и внутренних болезней МЗ РК

Название журнала:  Терапевтический вестник

Год выпуска:  2010

Номер журнала:  4

Страницы:  с. 7-9

Резюме на казахском языке:  Екі науқастың стент тромбозының пайда болуы туралы мәлімет Науқастың екеуінде де CYP3F5*3 *3 генотипі анықталды.

Резюме на английском языке:  We report cases of two patients in whom stent thrombosis were occurred.We analyzed the CYP3A5 gene polymorphism in these patients and determinedthat both patients were homozygous for the CYP3F5*3 allele.

Список литературы:  
1. FDA puplic health Web notification: information for physicians on subacute thromboses and hypersensitivity reactions with use of the Cordis CYPHER coronary stent/ October 29,2003/
2. Першуков И.В., Батыралиев Т.А. Тромбоз стентов, выделяющих лекарственные вещества, и его фармакологическая профилактика//Кардиология.-2007.- 7.-С.60-67.
3. Antithrombotic Trialist Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in highrisk patients//BMJ.-2002.-324.-P 71-86.
4. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. The CURE trial investigators//N. Engl. J. Med.-2001.-345.- P.494-502
5. Mehta S., Yusuf S.,Peters R. et al Effects of pretreatment with clopidogrel and aspirin followed by longterm therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study// Lancet.-2001.-358.-P. 527-533.
6. Gubel P.A., Bliden K.P., Hiatt B.L. et al Clopidogrel for coronary stenting: response variability, drug resistance and the effect of pretreatment platelet reactivity//Circulation.-2003.-107.-P.2908-2913.
7. Smith S, Judge H, Peters G, Armstrong M., Fontana P., Gaussem P., Daly M., Storey R. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the inhibitory effects of clopidogrel therapy// Platelets.- 2006.-17.-P.250-258
8. Hulot J., Bura A., Villard E, Azizi M, Remones V., Goyenvalle C, Aiach M., Lechat P., Gaussem P. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006,108:2244-2247
9. Buonamici P, Marcucci R, MiglioriniA, Gensini GF, SantiniA, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug- eluting stent thrombosis//J Am Coll Cardiol.- 2007.-49.-P. 2312-2317.
10. Plavix (Sanofi Aventis) Label Information. http://www.accessdata. fda.gov/drugsatfda_docs/label-/2009/020839s044lbl.pdf/, accessed on 11 December 2009.
11. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression//Nat Genet.- 2001.- 27.-P.383-91.
12. Jung-Won Suh, Bon-Kwon Koo, Shu-Ying Zhang, Kyung-Woo Park, Joo-Youn Cho, In-Jin Jang Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel// CMAJ.- 2006.- 12.- P. 1715-1722.
13. Smith SM, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy//Platelets.- 2006.-17.-P.250-25814. Simon T, Verstuyft C, Mary-Krause M Genetic determinants of response to clopidogrel and cardiovascular events //N Engl J Med. -2009.-360.- P.363-7515. Mega JL, Simon T., Anderson J et al CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis // Circulation.- 2009.-120:S598-S599

Электронный вариант:  скачать

---